Lykis Board Meeting Postponed Due to Non-Availability of Directors
The meeting of the Board of Directors,scheduled to consider and approve the unaudited Standalone and Consolidated Financial Results for the first quarter ended June 30, 2026 has been postponed due to the non-availability of directors.
What Happened and Why It Matters
Lykis Limited informed the stock exchange that it has postponed its Board meeting originally scheduled for Friday, July 24, 2026. The meeting was intended to review and approve the company's unaudited Standalone and Consolidated Financial Results for Q1 FY27.
While the postponement does not impact the company's day-to-day operations, it delays the release of quarterly earnings, which investors use to evaluate the company's financial performance and business outlook.
Business Impact and Strategic Relevance
- Financial Reporting: The approval and publication of Lykis Limited's Q1 FY27 unaudited Standalone and Consolidated financial results will be delayed until the Board meeting is rescheduled.
- Regulatory Compliance: The company confirmed that the revised Board meeting date will be communicated in accordance with Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- Trading Window: The trading window for dealing in the company's securities will remain closed and will reopen 48 hours after the declaration of the unaudited financial results for the quarter ended June 30, 2026.
What to Watch Next
Investors should monitor the announcement of the revised Board meeting date and the subsequent release of the company's Q1 FY27 unaudited financial results. They may also watch for any additional updates regarding the company's financial performance and corporate developments.
About Lykis Limited
Lykis Limited is an India-based FMCG company engaged in the manufacturing and marketing of personal care, healthcare, food products, and other consumer goods. The company's shares are listed on the Bombay Stock Exchange (BSE).
Disclaimer
Investments in the securities market are subject to market risks. Read all related documents carefully before investing. Registration granted by SEBI, and certification from NISM in no way guarantee the performance of the intermediary or provide any assurance of returns to investors. Choice Equity Broking Private Limited: SEBI Reg No. Broking - INZ000160131 ( BSE - 3299 ) | ( NSE - 13773 ) | ( MSEI - 73200 ) | ( MCX - 40585 ) | ( NCDEX - 01006 ). Depository Participant SEBI Reg. No. - IN - DP - 84 - 2015, DP ID CDSL - 12066900, NSDL ID - IN301895. Research Analyst - INH000000222 (CIN. NO.: U65999MH2010PTC198714)
Other News
SBI Life Insurance Reports 22% Rise in Q1 FY27 Profit, Strong Growth Across Key Metrics
SBI Life Insurance Company Limited reported strong financial performance for the quarter ended June 30, 2026 (Q1 FY27), with Profit After Tax (PAT) rising 22% year-on-year to Rupee7.2 billion. The insurer also recorded growth in Value of New Business (VoNB), Annualized Premium Equivalent (APE), Gross Written Premium (GWP), and Assets under Management (AuM).
ZF Steering Reports Q1 Fy27 PAT Rises 55% To Rs 12.37 Crore; Raises Aluminium Project Cost To Rs 150 Crore
ZF Steering Gear (India) Limited announced its financial results for the quarter ended June 30, 2026 (Q1 FY27) and approved a revision in the project cost of its wholly owned subsidiary's aluminium project. The Board increased the project's estimated investment from Rs 100 crore to Rs 150 crore to support capacity expansion and additional value-added manufacturing facilities.
Fineotex Chemical Reports Q1 Fy27 PAT Jumps 93% To Rs 48.21 Crore; Revenue More Than Doubles
Fineotex Chemical Limited announced its unaudited financial results for the quarter ended June 30, 2026 (Q1 FY27), reporting strong growth in revenue and profitability. The performance was supported by the integration of CrudeChem Technologies Group, operational efficiencies, and capacity expansion.